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Prenatal dexamethasone (DEX) exposure and high-fat (HF) intake are linked to
hypertension. We examined whether maternal melatonin therapy prevents programmed
hypertension synergistically induced by prenatal DEX plus postnatal HF in adult offspring.
We also examined whether DEX and melatonin causes renal programming using
next-generation RNA sequencing (NGS) technology. Pregnant Sprague-Dawley rats
received intraperitoneal dexamethasone (0.1mg/kg) or vehicle from gestational day 16
to 22. In the melatonin-treatment groups (M), rats received 0.01% melatonin in drinking
water during their entire pregnancy and lactation. Male offspring were assigned to five
groups: control, DEX, HF, DEX+HF, and DEX+HF+M. Male offspring in the HF group
were fed a HF diet from weaning to 4 months of age. Prenatal DEX and postnatal HF
diet synergistically induced programmed hypertension in adult offspring, which melatonin
prevented. Maternal melatonin treatment modified over 3000 renal transcripts in the
developing offspring kidney. Our NGS data indicate that PPAR signaling and fatty acid
metabolism are two significantly regulated pathways. In addition, maternal melatonin
therapy elicits longstanding alterations on renal programming, including regulation of
the melatonin signaling pathway and upregulation of Agtr1b and Mas1 expression in
the renin-angiotensin system (RAS), to protect male offspring against programmed
hypertension. Postnatal HF aggravates prenatal DEX induced programmed hypertension
in adult offspring, which melatonin prevented. The protective effects of melatonin on
programmed hypertension is associated with regulation of the RAS and melatonin
receptors. The long-term effects of maternal melatonin therapy on renal transcriptome
require further clarification.
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INTRODUCTION
Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous
indoleamine with pleiotropic bioactivities, including antioxidant
and anti-inflammatory properties, regulation of the circadian
rhythm and energy balance, control of reproduction, and
epigenetic regulation (Chen et al., 2013; Galano et al., 2013;
Cipolla-Neto et al., 2014; Tain et al., 2014b). Notably melatonin
deficiency causes hypertension whereas melatonin has been used
to treat hypertension in different experimental animal models
(Simko and Paulis, 2007).
Hypertension can originate from early life by a process
referred to as “developmental programming” (Ritz et al., 2011).
We previously reported thatmelatonin therapy during pregnancy
and lactation has long-term effect on adult offspring to prevent
the development of hypertension in a variety of programming
models, including maternal caloric restriction, prenatal, or
neonatal dexamethasone (DEX) exposure, and maternal high-
fructose intake (Wu et al., 2014; Tain et al., 2014a,c,d). Even
though several organs are involved in blood pressure (BP)
control, the developing kidney is particularly vulnerable to
the insults of programming in early life. Accordingly, renal
programming has been considered as a driving mechanism of
programmed hypertension (Paixão and Alexander, 2013).
Glucocorticoids are necessary for development and
maturation of the fetal organs. However, prenatal glucocorticoid
excess programs several adverse outcomes in adult offspring,
including hypertension (Moisiadis and Matthews, 2014). Our
previous research has shown that prenatal DEX exposure
induces programmed hypertension in adult offspring, which
can be protected by maternal melatonin treatment (Tain
et al., 2014a). Similar to melatonin, glucocorticoids plays a
crucial role in BP control, energy balance, and epigenetic
regulation (Nieuwenhuizen and Rutters, 2008; Moisiadis
and Matthews, 2014). While melatonin is beneficial to
reserving the adverse programming effects associated with
compromised pregnancies (Chen et al., 2013), its effects on
renal programming in the developing kidney remain unclear.
Therefore, we first employed the whole-genome RNA next-
generation sequencing (NGS) to analyze renal transcriptome
in the 1-week-old kidneys from prenatal DEX, melatonin, and
DEX + melatonin exposed male offspring, to capture candidate
genes and pathways responsible for primary programmed
changes.
Next, given that postnatal insults can act as a “second
hit” to deteriorate earlier programming induced by a first hit
(e.g., prenatal DEX), that fatty acid metabolism pathway was
significantly altered in response to both DEX and melatonin
from our NGS data, and that high-fat diets closely link to
the development of hypertension (Damjanovic and Barton,
2008), we hypothesized that prenatal DEX enhances offspring
vulnerability to postnatal HF-induced programmed hypertension
and that melatonin can protect the adult offspring against the
two-hit insults. The study was therefore designed to address
two specific questions: First, to examine renal transcriptome
at 1-week-old male offspring exposed to prenatal DEX and/or
melatonin; Second, to test if maternal melatonin therapy can
prevent programmed hypertension in the adult offspring exposed
to prenatal DEX plus postnatal high-fat diet and to explore the
underlying mechanisms.
MATERIAL AND METHODS
Animals and Experimental Design
The protocol was approved by the Institutional Animal Care
and Use Committee of the Kaohsiung Chang Gung Memorial
Hospital. This experiment was performed under the Guidelines
for Animal Experiments of Chang Gung Memorial Hospital and
ChangGungUniversity. Virgin Sprague-Dawley (SD) rats (12–16
weeks old) were obtained from the BioLASCO Taiwan Co., Ltd.
(Taipei, Taiwan).Male SD rats were caged with individual females
until mating was confirmed by observation of a vaginal plug. All
animals were housed in a room maintained at 22± 1◦C with 12-
h light/dark cycles (dark period from 1900 to 0700) in a facility
accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International.
The aim of the first series of experiments was to analyze renal
transcriptome in 1-week-old offspring kidney. To construct a
prenatal DEX exposure model, dexamethasone (0.1mg/kg body
weight [BW]) or vehicle was intraperitoneally administered to
pregnant SD rats from gestational day 16 to 22 (Tain et al.,
2014a). After birth, the subjects came from litters of eight pups
to standardize the received quantity of milk and maternal pup
care. Each litter was left with the mother until weaning; pups
were not weighed at birth to prevent maternal rejection. Because
hypertension occurs at a higher rate and at an earlier age in males
than females (Reckelhoff, 2001), only male offspring was selected
from each litter and used in subsequent experiments. Male
offspring were assigned to four groups: control, DEX, control +
melatonin, and DEX + melatonin. Melatonin-treated pregnant
rats received 0.01%melatonin in drinking water during the entire
pregnancy and lactation. The dose of melatonin used here was
based on our previous study (Tain et al., 2014a). Melatonin was
prepared two times a week by dissolving 10mg of melatonin in
1mL of 100% ethanol. This solution was then diluted with water
to a final concentration of 0.01%. Water bottles were wrapped
with aluminum foil to protect from light. Male offspring was
sacrificed at 1 week of age.
Our second series of experiments assessed the effects of
melatonin in a prenatal DEX plus postnatal high-fat (HF) diet
model. Five groups were studied: control, DEX, HF, DEX+HF,
and DEX+HF+M. DEX group was conducted as described
earlier. Male offspring rats in HF group received high-fat diet
(58% high-fat diet, Research Diet, D12331) from weaning to 4
months of age. Melatonin-treated pregnant rats received 0.01%
melatonin in drinking water during the entire pregnancy and
lactation.
BP was measured in conscious rats by an indirect tail-cuff
method (BP-2000, Visitech Systems, Inc., Apex, NC, USA) (Tain
et al., 2014a). One week prior to the experiment, rats were
adapted to restraint and tail-cuff inflation. Their tails were passed
through tail cuffs and secured in place with tape. Following
a 10-min warm-up period, 10 preliminary cycles of tail-cuff
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inflation were performed to allow the rats to adjust to the
inflating cuff. The BP measurements were taken between 1300
and 1700 each day. A total of five cycles were recorded at each
time point. Average of values from three stable measurements
was taken. At 16 weeks of age, male offspring were sacrificed
in the early light phase of the light-dark cycle. The midline
of the abdomen was opened, and the intestines were displaced
laterally to allow visualization of the aorta. The aorta was
dissected from the adjacent vena cava, connective tissue, and
fat. The aorta was cannulated with a 20- to 23-gauge butterfly,
heparinized blood samples were collected, the vena cava was cut,
and PBS was perfused until the kidneys were blanched. Kidneys
were harvested after perfusion, decapsulated, divided into cortex
and medulla, and stored at −80◦C for further analysis. Renal
melatonin level was measured using an ELISA kit (MyBioSource,
San Diego, CA, USA), according to the manufacturer’s protocol.
In short, 100mg kidney cortex was homogenized in 500µL PBS
and protein concentration was determined by Bradford assay
(Bio-Rad, Hercules, CA, USA). After two freeze-thaw cycles were
performed, tissue homogenate samples were centrifuged. The
supernatant was assayed. Duplicate determinations in 100µL
of homogenate samples were made and the average of two
measurements was used in subsequent statistical analysis of the
data. The melatonin level was quantified spectrophotometrically
at 450 nm. The results were expressed as pg melatonin permg of
protein.
Next-Generation Sequencing and Analysis
Kidney cortex (n = 3/group) isolated from first series of
experiment was used for whole-genome RNA next-generation
sequencing (NGS; Welgene Biotech Co., Ltd., Taipei, Taiwan).
Purified RNA was quantified at 260 nm (OD600) by using a ND-
1000 spectrophotometer (Nanodrop Technology, Wilmington,
DE, USA) and analyzed using a Bioanalyzer 2100 (Agilent
Technology) with RNA 6000 LabChip kit (Agilent Technologies).
All procedures were performed according to the Illumina
protocol. Using the TruSeq SBS Kit, the sequence was determined
by sequencing-by-synthesis technology. Raw sequences were
obtained using the Illumina GA Pipeline software CASAVA v1.8,
which was expected to generate 10 million reads per sample.
Quantification for gene expression was calculated as reads per
kilobase of exon per million mapped reads (RPKM) (Mortazavi
et al., 2008). For differential expression analysis, CummeRbund
(Illumina Inc.) was employed to perform statistical analyses of
gene expression profiles. The cuffdiff tool from the cuﬄinks
package (Trapnell et al., 2013) was run to calculate expression
changes and associated q-values (false discovery rate adjusted
p-values) for each gene between control and DEX, control and
M, as well as control and DEX+M groups. The output files
of cuffdiff were further annotated by adding gene functional
descriptions and Gene Ontology (GO) classifications. GO term
enrichment and fold enrichment or depletion for gene lists
of significantly up- and downregulated genes in kidney were
determined. GO analysis for significant genes was performed
using Kyoto Encyclopedia of Genes and Genomes (KEGG) and
NIH DAVID Bioinformatics Resources 6.7 (Dennis et al., 2003)
to identify regulated biological themes.
Quantitative Real-Time PCR Analysis
RNA was extracted as previously described procedures (Tain
et al., 2014a). Two-step quantitative real-time PCR (qPCR)
was conducted using Quantitect SYBR Green PCR Reagents
(Qiagen, Valencia, CA) on a LightCycler 480 Real-Time PCR
System (Roche Co., Germany). Several components of renin-
angiotensin system (RAS) analyzed in this study included
renin (Ren), (pro)renin receptor (Atp6ap2), angiotensinogen
(Agt), angiotensin converting enzyme-1 and -2 (Ace and Ace2),
angiotensin II type 1 & 2 receptor (Agtr1a and Agtr1b),
and angiotensin (1–7) receptor Mas1. R18S was used as a
housekeeping gene in all analyses as it did not change its
threshold cycle (CT) in control and the prenatal DEXmodel (Tain
et al., 2014a). Primers were designed using GeneTool Software
(Biotools, Edmonton, Alberta, Canada) (Table S1). All samples
were run in duplicate. For the relative quantification of gene
expression, the comparative CT method was employed. The
averaged CT was subtracted from the corresponding averaged
r18S value for each sample, resulting in 1CT. 11CT was
achieved by subtracting the average control 1CT value from the
average experimental 1CT. The fold-increase was established by
calculating 2−11CT for experimental vs. reference samples.
Western Blot
Western blot analysis was performed as we published previously
(Tain et al., 2014a,d; Wu et al., 2014). Three melatonin receptors,
including melatonin receptor-1 (MT1), and -2 (MT2), and
RORα, were analyzed. We used the following antibodies: a goat
anti-rat MT1 antibody (1:1000, overnight incubation; Santa Cruz
Biotechnology, Santa Cruz, CA, USA); a rabbit anti-rat MT2
antibody (1:1000, overnight incubation; Biorbyt, AllBio Science
Inc., Taichung, Taiwan); and a rabbit anti-rat RORα antibody
(1:2000, overnight incubation; Proteintech Group, Inc., Chicago,
IL, USA). Bands of interest were visualized using SuperSignal
West Pico reagent (Pierce; Rockford, IL, USA) and quantified
by densitometry as integrated optical density (IOD), factored for
Ponceau S red (PonS) staining to correct for any variations in
total protein loading and for an internal standard. The protein
abundance was represented as IOD/PonS.
Statistics
Normally distributed data were given as mean ± S.E.M. For
most parameters, statistical analysis was performed using One-
way ANOVAwith Tukey’s post-hoc test formultiple comparisons.
BP was analyzed by Two-way repeated-measures ANOVA and
Tukey’s post-hoc test. A P < 0.05 was considered statistically
significant. All analyses were performed using the Statistical
Package for the Social Sciences software (SPSS; IBM, Armonk,
NY, USA).
RESULTS
In the first series of experiments, we analyzed differential gene
expression induced by DEX, melatonin, and DEX + melatonin
in the 1-week-old male offspring kidney. Among the differential
expressed genes (DEGs), a total of 1425 genes (958 up- and
467 down-regulated genes by DEX vs. control) met the selection
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criteria of (1) genes that changed by reads per kilobase of
transcript per million mapped reads (RPKM) >0.3 and (2)
minimum of two-fold difference in normalized read counts
between group. Next, 3228 DEGs (2684 up- and 544 down-
regulated genes) was observed in melatonin vs. control. In
addition, there was a total of 2493DEGs (512 up- and 1981 down-
regulated genes) between DEX + melatonin and control group.
Among them, 256 shared genes were identified (Table S2). Genes
shared by different exposures were represented graphically by the
Venn diagram shown in Figure 1.
We next used DAVID v6.7 (Dennis et al., 2003) to gain
biological insight from our gene lists. We searched for KEGG
pathways that are statistically enriched among three groups, and
found 12, 55, and 36 such pathways in the DEX, melatonin,
and DEX + melatonin group, respectively (Table S3). We
observed that 5 KEGG pathways were shared by the three
groups, including chemokine signaling pathway, axon guidance,
Hedgehog signaling pathway, focal adhesion, and PPAR signaling
pathway. Among 256 shared genes, we found three significantly
regulated KEGG pathways, including PPAR signaling, drug
metabolism, and fatty acid metabolism (Figure 1).
We also examined three systems which might be involved
in the DEX-induced programmed hypertension and protective
effects of melatonin based on published data and our preliminary
results. First, we looked at the renin-angiotensin system
(RAS). RAS has been thought to contribute to programmed
hypertension (Paixão and Alexander, 2013; Tain et al., 2014a).
Our NGS data showed that RAS is a significantly regulated
KEGG pathway in both melatonin and DEX + melatonin
group (Table S2). The identified DEGs in RAS include Agt
in DEX vs. control; Ren, Ace, Ace2, and Mas1 in melatonin
group vs. control; and Ace and Mas1 in DEX + melatonin
vs. control (Figure 2A). Next, we considered that maternal
FIGURE 1 | Venn diagram depicting unique and shared (overlapping
circles) sets of differential expressed genes (DEGs), between prenatal
dexamethasone exposure (DEX, gray circle), melatonin treatment (M,
white circle), and prenatal dexamethasone plus melatonin treatment
(DEX+M, black circle). A total of three shared KEGG pathways are listed in
the lower panel.
melatonin therapy might regulate the synthesis, metabolism, and
signaling pathway of melatonin in the offspring kidney. We
observed that genes involved in the biosynthetic pathway of
melatonin were significantly upregulated, including Tph1, Ddc,
and Asmt (Figure 2B). The Cyp1b1, a cytochrome P450 enzyme
responsible for melatonin degradation, was also upregulated
in melatonin group vs. control. Despite Mtnr1a (encoded
for melatonin receptor 1) was undetectable, other melatonin
receptorsMtnr1b, Rora, and Rorb were upregulated in melatonin
group (Figure 2B). These data demonstrated that maternal
melatonin treatment upregulates the synthesis, degradation,
and downstream signaling pathway of melatonin in offspring
kidney. Finally, mindful of the fact that the most common
regulated KEGG pathways are related to lipid metabolism
and insulin signaling, we also examined adiponectin (Adipoq)
and its receptors (Adipor1 and Adipor2), genes involved in
fatty acid metabolism (Acadsb), and insulin signaling pathway
(Figure 2C). Maternal melatonin therapy significantly increased
the expression of Adipoq (Fold change [FC] = 6.3), Adipor2
(FC = 6.76), Irs1 (FC = 3.44), Irs2 (FC = 2.66), Ppargc1a (FC =
3.2), Foxo1 (FC= 6.81), andAcadsb (FC= 3.2). Data by our NGS
results described that maternal melatonin induced alterations of
genes involved in insulin signaling and fatty acid degradation.
Whether melatonin can regulate insulin sensitivity and fatty acid
degradation to protect against programmed hypertension awaits
further evaluation.
In the next series of experiments, we observed that male
pup mortality rates, body weight, and kidney weight were not
different among the groups (Table 1). The systolic and diastolic
BPs and mean arterial pressure (MAP) of DEX group were
significantly higher than those in the control group at 16 weeks
of age (Figure 3). Postnatal HF intake caused a marked increase
in BPs, and the systolic BP and MAP achieved were similar to
those in DEX group. The DEX+HF group had the highest BPs
compared to DEX, HF, and control group. These findings showed
the synergistic interaction between the effects of prenatal DEX
and postnatal HF on the elevation of BP. Of note, the increase of
BPs was attenuated by maternal melatonin therapy (Figure 3).
Next, we evaluated the mRNA expression of RAS components
in the prenatal DEX plus postnatal HF two-hit model. As shown
in Figure 4, prenatal DEX exposure significantly upregulated
mRNA expression ofRen (FC= 7.05) andAtp6ap2 (FC= 7.84) in
the 16-week-old kidneys. Postnatal HF diets induced Agt (FC =
4.22), Ace (FC = 3), and Ace2 (FC = 2.84) mRNA expression
in kidney. DEX+HF led to increased Ren (FC = 5.35), Atp6ap2
(FC = 6.45), Agt (FC = 3.73), Ace (FC = 3.35), and Ace2 (FC =
3.19) in the kidney. Maternal melatonin therapy increased renal
Ren (FC = 6.46), Atp6ap2 (FC = 7.71), Agt (FC = 4.96), Ace
(FC = 4.01), Ace2 (FC = 3.21), Agtr1b (FC = 4.25), and Mas1
(FC= 2.51) mRNA expression in the DEX+HF+M group.
Furthermore, we examined whether melatonin and its
receptors were altered in the programmed hypertension in
response to DEX, HF, and melatonin. As shown in Figure 5,
renal MT1 level was high in the DEX+HF group (+95.3%)
vs. control. MT2 protein abundance in the kidney was lower
in the HF (−40.4%), DEX+HF (−67.4%), and DEX+HF+M
groups (−34.2%) than that in control and DEX group.
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FIGURE 2 | Effects of prenatal dexamethasone exposure (DEX), melatonin treatment (M), and prenatal dexamethasone plus melatonin treatment
(DEX+M) on gene expression in the (A) renin-angiotensin system, (B) synthesis, metabolism, and signaling pathway of melatonin, and (C) lipid
metabolism and insulin signaling in the 1-week-old offspring kidney.
TABLE 1 | Weights and functional parameters.
Control DEX HF DEX+HF DEX+HF+M
N = 7 N = 8 N = 7 N = 8 N = 8
Mortality (%) 0 0 0 0 0
Body weight (BW) (g) 578±10 555± 19 550±13 603± 11 613± 10
Left kidney weight (g) 1.93±0.06 2.05± 0.06 1.98±0.05 2.1± 0.07 2.14± 0.08
Left kidney weight/100 g BW 0.33±0.01 0.37± 0.01 0.36±0.01 0.35± 0.011 0.35± 0.01
Systolic blood pressure (mmHg) 150±2 170± 58* 172±3* 180± 2*# 154± 2#†‡
Diastolic blood pressure (mmHg) 76±3 86± 4 95±8* 109± 4*# 76± 2†‡
Mean arterial pressure (mmHg) 101±2 114± 3* 121±2* 133± 3*# 102± 2#†‡
*P < 0.05 vs. control; #P < 0.05 vs. DEX; †P < 0.05 vs. HF; ‡P < 0.05 vs. DEX+HF.
RORα protein level was not different among the five groups
(Figure 5). However, maternal melatonin therapy increased renal
melatonin level compared to control and the DEX group
(Figure 5E).
DISCUSSION
This study provides insight into a novel mechanism by which
maternal melatonin therapy prevents prenatal DEX and postnatal
HF intake synergistically induced programmed hypertension in
adult male offspring. The main findings can be summarized as
follow: (1) a total of 256 differential expressed genes (DEGs)
were shared by prenatal DEX, melatonin, and DEX +melatonin
exposure in the 1-week-old male offspring kidney; (2) maternal
melatonin treatment upregulates the synthesis, degradation, and
downstream signaling pathway of melatonin in the offspring
kidney; (3) prenatal DEX and postnatal HF diet synergistically
induced programmed hypertension in adult offspring, which
maternal melatonin prevented; and (4) the protective effects of
melatonin on programmed hypertension in this two-hit model
is associated with alterations of genes in RAS and melatonin
receptors.
Despite the well-documented anti-hypertensive effects of
melatonin in adults (Simko and Paulis, 2007; Reiter et al.,
2010), limited data are available regarding dams under melatonin
therapy during pregnancy and lactation causing long-term BP-
lowering effects in their adult offspring, especially focused on
renal programming. To the best of our knowledge, our study is
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FIGURE 3 | Effects of prenatal dexamethasone exposure (DEX),
postnatal high-fat diet (HF), prenatal DEX plus postnatal (DEX+HF),
and maternal melatonin treatment (DEX+HF+M) on systolic blood
pressure. Blood pressure was measured in conscious rats by an indirect
tail-cuff method between 3 and 16 weeks of age. N = 7–8/group. *P < 0.05
vs. control; #P < 0.05 vs. DEX; †P < 0.05 vs. HF; ‡P < 0.05 vs. DEX+HF.
the first to show that maternal melatonin therapy can prevent
programmed hypertension in adult rats synergistically induced
by prenatal DEX and postnatal HF diet. It is consistent with our
recent reports showing that maternal melatonin therapy prevents
programmed hypertension in a variety of programming models
(Tain et al., 2014a,c,d; Wu et al., 2014).
Given that nephrogenesis occurs from late gestation to
postnatal week 1–2 in rats, maternal melatonin treatment used in
this study covered the whole nephrogenesis period. In agreement
with previous studies (Korkmaz et al., 2012; Tain et al., 2014b),
we observed that 6 weeks of maternal melatonin therapy is likely
to serve as an inducer of gene expression in the developing
kidney. Regardless of whether melatonin therapy has a benign
safety profile for pregnant women (Chen et al., 2013), whether
maternal melatonin therapy might cause long-term epigenetic
changes leading to adverse effects in adult offspring remains to be
clarified. Our data also indicate that early melatonin therapy may
deprogram high-fat induced programmed process and prevent
the development of hypertension during later life.
Melatonin has been proposed to prevent obesity-
related disorders (Cipolla-Neto et al., 2014). Our NGS data
demonstrated that maternal melatonin can upregulate several
genes involved in energy control in offspring kidney, which
may increase insulin sensitivity and fatty acid degradation. It is
possible that early melatonin therapy elicit programmed process
for the regulation of fatty acids in the offspring that helps to
moderate the effects of postnatally HF diet.
Next, some particular candidate genes/pathways related to
the programmed hypertension have been studied in different
models of developmental programming, such as the RAS (Ritz
et al., 2011; Paixão and Alexander, 2013). Indeed, the RAS
plays an essential role in kidney development as well as in
programmed hypertension (Manning, 2004; Yosypiv, 2014).
Our results showed that maternal melatonin therapy increased
Agtr1b (encoded for AT2R) andMas1 (encoded for Mas) mRNA
expression in the kidney. It is well-established that the signaling
triggered by AT2R or Mas activation represents an endogenous
counter-regulatory pathway within the RAS, that is in opposition
to the vasoconstrictor arm of the RAS (Chappell et al., 2014).
Thus, one might expect maternal melatonin therapy to adjust
the RAS in a way that opposes the development of hypertension
in the DEX+HF+M group, similar to our previous report in a
rat model of maternal caloric restriction-induced programmed
hypertension (Hsu et al., 2014).
Another possible protective mechanism of melatonin on
programmed hypertension is related to its regulation on the
melatonin pathway in the offspring kidney. Our NGS data
demonstrated that maternal melatonin therapy programmed
synthesis, metabolism, and signaling pathway of melatonin in the
developing offspring kidney. Importantly, maternal melatonin
increased renal melatonin level, and restored two-hit insults
induced increased MT1 and decreased MT2 protein levels
in adult offspring. MT1 has been found to mediate vascular
constriction, while MT2 mediates vasodilatation (Doolen et al.,
1998). These findings indicate early melatonin therapy elicits
a persistent effect on the melatonin level and its receptors,
at least in part, to prevent prenatal DEX and postnatal HF
synergistically induced programmed hypertension. Given that
MT2 defects link to the development of diabetes (Bonnefond
et al., 2012), and that a strong association between HF intake
and diabetes, whether early targeting onmelatonin/MT2 pathway
can reduce offspring vulnerability to postnatal HF-induced
programming deserves further study. Furthermore, prenatal
DEX and postnatal HF induced programmed hypertension
in adult offspring, while both altered gene expression of the
RAS components and melatonin receptors differentially. These
observations suggest that different insults might generate a
complex set of programming responses; some pathways have
commonality, but others may not, despite the manifests of
same phenotype-hypertension. Thus, the implications of other
mechanisms involved in melatonin-induced deprogramming
deserve further clarification.
In NGS dataset, we observed two important KEGG pathways
shared by DEX, M, and DEX+M group, including PPAR
signaling and fatty acid metabolism. We have recently shown
that PPAR signaling pathway is identified as a common
pathway related to programmed hypertension in the caloric
restriction, maternal diabetes, and high-fructose intake models
(Tain et al., 2015). The PPAR signaling pathway has been
well-studied in established hypertension and is becoming a
therapeutic target for hypertension (Duan et al., 2009). Next,
fatty acid metabolism was identified as a commonly regulated
KEGG pathway in both the caloric restriction and high-fructose
intake model in our previous study (Tain et al., 2015). Here
we demonstrated that maternal melatonin induced increases
in fatty acid degradation and insulin sensitivity. Therefore,
additional studies are required to unravel whether protective
effects of melatonin on programmed hypertension are via the
PPAR signaling and fatty acid metabolism pathways in other
programmed models.
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FIGURE 4 | Prenatal dexamethasone exposure (DEX), postnatal high-fat diet (HF), prenatal DEX plus postnatal (DEX+HF), and maternal melatonin
treatment (DEX+HF+M) effects on gene expression of components of renin-angiotensin system, including (A) Ren, (B) Atp6ap2, (C) Agt, (D) Ace, (E)
Ace2, (F) Agtr1a, (G) Agtr1b, and (H) Mas1 in the offspring kidney at 16 weeks of age. N = 6/group. *P < 0.05 vs. control; #P < 0.05 vs. DEX; †P < 0.05 vs.
HF; ‡P < 0.05 vs. DEX+HF.
FIGURE 5 | Representative western blots showing (A) melatonin receptor-1 (MT1) (37 kDa), and −2 (MT2) (40 kDa), and RORα (59 kDa) bands in control,
prenatal dexamethasone exposure (DEX), postnatal high-fat diet (HF), prenatal DEX plus postnatal (DEX+HF), and melatonin treatment (DEX+HF+M)
offspring rats at 16 weeks of age. Relative abundance of renal cortical (B) MT1, (C) MT2, and (D) RORα as quantified. (E) Effect of DEX, HF, and melatonin on
renal melatonin level. N = 6/group. *P < 0.05 vs. control; #P < 0.05 vs. DEX; ‡P < 0.05 vs. DEX+HF.
In conclusion, postnatal HF diet enhanced prenatal DEX-
induced programmed hypertension in adult offspring, which
can be prevented by maternal melatonin therapy. Maternal
melatonin therapy has long-term effects on renal programming,
including regulation of the synthesis and signaling pathway of
melatonin and increases of Agtr1b and Mas1 mRNA expression.
By providing candidate genes and pathways responsible for
programmed hypertension, our results are of significance to the
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development of novel interventions in the prevention of renal
programming and hypertension in children exposed to prenatal
glucocorticoid and postnatal high-fat intake.
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